The global non-invasive prenatal testing (NIPT) market size is expected to reach USD 6.56 billion by 2028 according to a new study by Polaris Market Research. The report “Non-Invasive Prenatal Testing (NIPT) Market Share, Size, Trends, Industry Analysis Report, By Gestation Period (0-12 weeks, 13-24 weeks, 25-36 weeks); By Component (Consumables, Instruments, Software, Services); By Method; By Application; By End-Use; By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The market demand for non-invasive prenatal testing is expected to increase during the forecast period owing to growth in the occurrence of genetic disorders, increasing awareness regarding early fetal testing, and advancing maternal age. The significant market growth in healthcare infrastructure, technological advancements, and favorable regulations are some factors expected to provide growth opportunities during the forecast period.
The gestation period segment has been divided into 0-12 weeks, 13-24 weeks, 25-36 weeks. Testing performed for 13 – 24 weeks involves blood tests and ultrasound to detect genetic disorders and neural tube defects. Ultrasounds are also used in this period to examine the anatomy and associated disorders. There has been a high demand for consumables required during non-invasive prenatal testing. The rising awareness regarding fetal testing, coupled with technological advancements, supportive government regulations, and advanced healthcare infrastructure boosts the market growth.
Non-invasive prenatal testing is used for the detection of Monosomy, Trisomy, Microdeletion Syndrome, and Others. The trisomy accounted for a major share of the global market for non-invasive prenatal testing owing to high accuracy in detection of trisomy, growing maternal age, and increasing awareness regarding early and non-invasive fetal diagnosis. The test for detection of trisomy is performed after 10 weeks for enhanced safety, reliability, and accuracy for detection of the three common trisomy including chromosomes 21, 18, and 13.
The different methods of non-invasive prenatal testing include cell-free DNA in maternal plasma tests, ultrasound detection, biochemical screening tests, and others. The cell-free DNA in the maternal plasma segment is expected to grow significantly during the forecast period. The increasing accuracy in the detection of chromosomal abnormalities through this method, growing patient awareness, and efficient planning for pregnancy management are some factors driving the growth of this segment.
Non-invasive prenatal testing services are offered in diagnostic centers, hospitals, clinics, and others. The diagnostic centers segment accounted for the highest share in 2020. The increasing occurrence of chromosomal abnormalities coupled with supportive government initiatives supports the growth of this segment. The presence of specialized equipment, advanced healthcare infrastructure, and expert professionals further encourage patients to visit diagnostic centers.
North America dominated the global NIPT market in 2020 and is expected to maintain its dominance over the forecast period. High living standards, significant investment in healthcare services, and increasing occurrence of chromosome abnormalities support market growth in this region. However, Asia-Pacific is expected to exhibit significant growth during the forecast period. Increasing population coupled with increasing awareness regarding fetal testing fuels growth in this region. Leading global players are expanding their presence in developing nations of China, Japan, India, and South Korea to tap the growth opportunities offered by these countries.
On account of the technological advancements, and greater need to cater to customer requirements, companies are collaborating in order to strengthen the market presence and gain market share. Broadening of the product portfolio is another trend that is visible in the industry.
Some of the major market participants include Agilent Technologies, Inc., Laboratory Corporation of America Holdings, Illumina, Inc., F. Hoffman-La Roche Ltd., Yourgene Health, Perkinelmer, Inc., GE Healthcare, Quest Diagnostics, Thermo Fisher Scientific, Inc., Sequenom, Qiagen N.V., Koninklijke Philips N.V., Natera, Inc., Beijing Genomics Institute, and Pacific Biosciences of California, Inc.